View Older Stories

Feb 11, 2026 08:02AM Citius Oncology signs exclusive European distribution deal with Uniphar

Feb 11, 2026 08:00AM Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Dec 23, 2025 04:31PM Citius Pharmaceuticals launches cancer drug LYMPHIR following FDA approval

Dec 23, 2025 04:30PM Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025 04:30PM Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 10, 2025 04:30PM Citius Oncology closes $18 million stock offering at $1.09 per share

Dec 10, 2025 04:30PM Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025 08:30AM Citius Oncology raises $18 million in stock offering for LYMPHIR launch

Dec 9, 2025 08:30AM Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025 08:37AM Citius Oncology partners with Er-Kim for LYMPHIR distribution in Turkey, GCC

Dec 4, 2025 08:37AM Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Dec 1, 2025 12:08PM Citius Oncology launches LYMPHIR cancer treatment nationwide

Dec 1, 2025 12:00PM Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Nov 25, 2025 08:00AM Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 21, 2025 08:37AM Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Oct 21, 2025 04:30PM Citius Pharmaceuticals closes $6 million direct offering

Oct 21, 2025 04:30PM Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025 08:01AM Citius Pharmaceuticals raises $6 million in registered direct offering

Oct 21, 2025 08:00AM Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 20, 2025 08:38AM Citius Oncology signs distribution deal with McKesson for LYMPHIR launch

Oct 20, 2025 08:37AM Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 17, 2025 05:00PM Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Oct 16, 2025 08:47AM Citius Oncology partners with EVERSANA for LYMPHIR drug launch

Oct 16, 2025 08:47AM Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oct 7, 2025 08:47AM Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Sep 10, 2025 04:30PM Citius Oncology closes $9 million equity offering

Sep 10, 2025 04:30PM Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 9, 2025 08:30AM Citius Oncology prices $9 million offering at $1.75 per share

Sep 9, 2025 08:30AM Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Aug 22, 2025 08:47AM Citius Oncology deploys AI platform ahead of LYMPHIR launch

Aug 22, 2025 08:47AM Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Aug 12, 2025 04:30PM Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025 04:30PM Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Jul 17, 2025 04:30PM Citius Oncology closes $9 million public offering

Jul 17, 2025 04:30PM Citius Oncology Announces Closing of $9.0 Million Public Offering

Jul 17, 2025 04:30PM Citius Oncology Announces Closing of $9.0 Million Public Offering

Jul 16, 2025 09:15AM Citius Oncology prices $9 million public offering at $1.32 per share

Jul 16, 2025 09:15AM Citius Oncology Announces Pricing of $9.0 Million Public Offering

Jul 15, 2025 08:32AM Citius Oncology signs distribution deal with Cencora for LYMPHIR

Jul 15, 2025 08:32AM Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Jul 8, 2025 08:34AM Citius Pharmaceuticals regains Nasdaq compliance

Jul 8, 2025 08:34AM Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 17, 2025 08:10AM Citius Oncology (CTOR) Anticipates Commercial Launch of LYMPHIR in 2025

Jun 17, 2025 08:08AM Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Jun 12, 2025 08:35AM Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 10, 2025 07:01AM Citius Pharmaceuticals (CTXR) Prices $15.8M Offering at $1.22/sh

Jun 10, 2025 07:00AM Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 9, 2025 08:57AM Citius Oncology (CTOR) stock soars on distribution deal

Jun 9, 2025 08:38AM Citius (CTOR) enters distribution agreement with Cardinal Health (CAH)

Jun 9, 2025 08:37AM Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

View Older Stories